Neuregulin-1 protects against doxorubicin-induced apoptosis in cardiomyocytes through an akt-dependent pathway

Physiological Research

Volumn 62, Issue 4, 2013, Pages 379-385

  An, T ^a   Zhang, Y ^a   Huang, Y ^a   Zhang, R ^a   Yin, S ^a   Guo, X ^a   Wang, Y ^a   Zou, C ^a   Wei, B ^a   Lv, R ^a   Zhou, Q ^a   Zhan, J ^a  

^a FUWAI HOSPITAL   (China)

Author keywords

Akt; Apoptosis; Cardiomyocyte; Doxorubicin; Neuregulin

Indexed keywords

ANTINEOPLASTIC ANTIBIOTIC; APOPTOSIS REGULATORY PROTEIN; DOXORUBICIN; NEU DIFFERENTIATION FACTOR; NRG1 PROTEIN, HUMAN; PROTECTIVE AGENT; PROTEIN KINASE B; PROTEIN KINASE INHIBITOR; RECOMBINANT PROTEIN;

ANIMAL; APOPTOSIS; ARTICLE; CELL CULTURE; CELL PROTECTION; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; ENZYME ACTIVATION; ENZYMOLOGY; HEART MUSCLE CELL; HUMAN; METABOLISM; NEWBORN; PATHOLOGY; PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT;

ANIMALS; ANIMALS, NEWBORN; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CELLS, CULTURED; CYTOPROTECTION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; ENZYME ACTIVATION; HUMANS; MYOCYTES, CARDIAC; NEUREGULIN-1; PHOSPHORYLATION; PROTECTIVE AGENTS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION;

EID: 84883522692     PISSN: 08628408     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. BIAN Y, SUN M, SILVER M, HO KK, MARCHIONNI MA, CAGGIANO AO, STONE JR, AMENDE I, HAMPTON TG, MORGAN JP, YAN X: Neuregulin-1 attenuated doxorubicin-induced decrease in cardiac troponins. Am J Physiol Heart Circ Physiol 297: H1974-H1983, 2009.
2. BRISTOW MR, BILLINGHAM ME, MASON JW, DANIELS JR: Clinical spectrum of anthracycline antibiotic cardiotoxicity. Cancer Treat Rep 62: 873-879, 1978.
3. CHAANINE AH, HAJJAR RJ: AKT signalling in the failing heart. Eur J Heart Fail 13: 825-829, 2011.
4. CRONE SA, ZHAO YY, FAN L, GU Y, MINAMISAWA S, LIU Y, PETERSON KL, CHEN J, KAHN R, CONDORELLI G, ROSS J JR, CHIEN KR, LEE KF: ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 8: 459-465, 2002.
5. FANG SJ, WU XS, HAN ZH, ZHANG XX, WANG CM, LI XY, LU LQ, ZHANG JL: Neuregulin-1 preconditioning protects the heart against ischemia/reperfusion injury through a PI3K/Akt-dependent mechanism. Chin Med J (Engl) 123: 3597-3604, 2010.
6. FULLER SJ, SIVARAJAH K, SUGDEN PH: ErbB receptors, their ligands, and the consequences of their activation and inhibition in the myocardium. J Mol Cell Cardiol 44: 831-854, 2008.
7. GAO R, ZHANG J, CHENG L, WU X, DONG W, YANG X, LI T, LIU X, XU Y, LI X, ZHOU M: A Phase II, randomized, double-blind, multicenter, based on standard therapy, placebo-controlled study of the efficacy and safety of recombinant human neuregulin-1 in patients with chronic heart failure. J Am Coll Cardiol 55: 1907- 1914, 2010.
8. HORIE T, ONO K, NISHI H, NAGAO K, KINOSHITA M, WATANABE S, KUWABARA Y, NAKASHIMA Y, TAKANABE-MORI R, NISHI E, HASEGAWA K, KITA T, KIMURA T: Acute doxorubicin cardiotoxicity is associated with miR-146a-induced inhibition of the neuregulin-ErbB pathway. Cardiovasc Res 87: 656-664, 2010.
9. JIE B, ZHANG X, WU X, XIN Y, LIU Y, GUO Y: Neuregulin-1 suppresses cardiomyocyte apoptosis by activating PI3K/Akt and inhibiting mitochondrial permeability transition pore. Mol Cell Biochem 370: 35-43, 2012.
10. KURAMOCHI Y, GUO X, SAWYER DB: Neuregulin activates erbB2-dependent src/FAK signaling and cytoskeletal remodeling in isolated adult rat cardiac myocytes. J Mol Cell Cardiol 41: 228-235, 2006.
11. LIU X, GU X, LI Z, LI X, LI H, CHANG J, CHEN P, JIN J, XI B, CHEN D, LAI D, GRAHAM R M, ZHOU M: Neuregulin-1/erbB-activation improves cardiac function and survival in models of ischemic, dilated, and viral cardiomyopathy. J Am Coll Cardiol 48: 1438-1447, 2006.
12. MATSUI T, ROSENZWEIG A: Convergent signal transduction pathways controlling cardiomyocyte survival and function: the role of PI 3-kinase and Akt. J Mol Cell Cardiol 38: 63-71, 2005.
13. MATSUI T, TAO J, DEL MONTE F, LEE KH, LI L, PICARD M, FORCE TL, FRANKE TF, HAJJAR RJ, ROSENZWEIG A: Akt activation preserves cardiac function and prevents injury after transient cardiac ischemia in vivo. Circulation 104: 330-335, 2001.
14. NISHIDA K, YAMAGUCHI O, OTSU K: Crosstalk between autophagy and apoptosis in heart disease. Circ Res 103: 343-351, 2008.
15. ODIETE O, HILL MF, SAWYER DB: Neuregulin in cardiovascular development and disease. Circ Res 111: 1376- 1385, 2012.
16. OZCELIK C, ERDMANN B, PILZ B, WETTSCHURECK N, BRITSCH S, HUBNER N, CHIEN KR, BIRCHMEIER C, GARRATT AN: Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proc Natl Acad Sci USA 99: 8880-8885, 2002.
17. PENTASSUGLIA L, TIMOLATI F, SEIFRIZ F, ABUDUKADIER K, SUTER TM, ZUPPINGER C: Inhibition of ErbB2/neuregulin signaling augments paclitaxel-induced cardiotoxicity in adult ventricular myocytes. Exp Cell Res 313: 1588-1601, 2007.
18. POPELOVA O, STERBA M, HASKOVA P, SIMUNEK T, HROCH M, GUNCOVA I, NACHTIGAL P, ADAMCOVA M, GERSL V, MAZUROVA Y: Dexrazoxane-afforded protection against chronic anthracycline cardiotoxicity in vivo: effective rescue of cardiomyocytes from apoptotic cell death. Br J Cancer 101: 792-802, 2009.
19. RUSSELL KS, STERN DF, POLVERINI PJ, BENDER JR: Neuregulin activation of ErbB receptors in vascular endothelium leads to angiogenesis. Am J Physiol 277: H2205-H2211, 1999.
20. SAWYER DB, ZUPPINGER C, MILLER TA, EPPENBERGER HM, SUTER TM: Modulation of anthracyclineinduced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity. Circulation 105: 1551-1554, 2002.
21. SHIRAISHI I, MELENDEZ J, AHN Y, SKAVDAHL M, MURPHY E, WELCH S, SCHAEFER E, WALSH K, ROSENZWEIG A, TORELLA D, NURZYNSKA D, KAJSTURA J, LERI A, ANVERSA P, SUSSMAN MA: Nuclear targeting of Akt enhances kinase activity and survival of cardiomyocytes. Circ Res 94: 884-891, 2004.
22. SINGAL PK, ILISKOVIC N: Doxorubicin-induced cardiomyopathy. N Engl J Med 339: 900-905, 1998.
23. STERBA M, POPELOVA O, VAVROVA A, JIRKOVSKY E, KOVARIKOVA P, GERSL V, SIMUNEK T: Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection. Antioxid Redox Signal 18: 899-929, 2013.
24. SWAIN SM, WHALEY FS, EWER MS: Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 97: 2869-2879, 2003.
25. TAKEMURA G, FUJIWARA H: Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management. Prog Cardiovasc Dis 49: 330-352, 2007.
26. TAN WQ, WANG K, LV DY, LI PF: Foxo3a inhibits cardiomyocyte hypertrophy through transactivating catalase. J Biol Chem 283: 29730-29739, 2008.
27. ZHAO YY, SAWYER DR, BALIGA RR, OPEL DJ, HAN X, MARCHIONNI MA, KELLY RA: Neuregulins promote survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes. J Biol Chem 273: 10261-10269, 1998